Cancer treatment for one of the most aggressive forms of breast cancer has been boosted by a recent genetic discovery.
Scientists at the Cancer Institute at NYU Langone Medical Center have identified the gene eIF4G1 to be particularly expressed in most incidents of inflammatory breast cancer, which is a potent form of breast cancer that often leaves patients dead within a time-frame of 18 months to two years.
Dr Robert Schneider, associate director for translational research at The Cancer Institute, co-director of breast cancer research, and the Albert B Sabin Professor of Molecular Pathogenesis at NYU School of Medicine, commented: "The good news is that we're beginning to understand IBC at both a molecular and genetic level.
"We believe this gene is a target for new drug discovery, and we also believe it is possible to silence the gene without hurting normal cells."
Inflammatory breast cancer is particularly difficult to diagnose as its symptoms do not always include a lump, which would otherwise be detected in an ultrasound or mammogram